Phase 2 N=34 Restoring Cognitive Control (ReCon) in Acute Nicotine Withdrawal
Impulse Control Disorders
Primary: Safety and Tolerability of SXC-2023. — 0; 0; 0; 0 Events
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=24 Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Brain and Central Nervous System Tumors
Primary: Overall Survival — 19.1 months
Phase 2 N=65 Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer
Pancreatic Neoplasms · Pancreatic Cancer · Cancer of Pancreas
Primary: Number of Adverse Events in Each Cohort With Grade 1 Through 5 Related to Study Drug — 0; 0; 0; 1 Adverse events
Phase 2 N=248 Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)
Mesothelioma
Primary: Progression-free Survival (PFS), [95% CI] — 4.3; 4.5 months — p=0.859125
Phase 2 N=27 Trial of TRC105 and Sorafenib in Patients With HCC
Hepatocellular Carcinoma
Primary: Number of Patients Who Experience Dose Limiting Toxicities by Dose Level — 1; 0 Participants
Phase 2 N=25 Evaluation of the Inhibitory Effects of Topical Ivermectin on Markers of Rosacea Specific Inflammation.
Rosacea
Primary: Relative Trypsin-like Enzyme Activity — 1.10 percentage of baseline
Phase 2 N=45 B Cell Induction in Pediatric Lung Transplantation
Lung Transplant
Primary: Earliest Time to Any of the Following Events: Chronic Allograft Dysfunction, Listed for Retransplant or Death — NA; 703 Days — p=0.514
Phase 2 N=167 A Study to Evaluate ABT-494 (Upadacitinib) in Adults With Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
Primary: Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 16 — -23.0; -39.4; -61.7; -74.4 percent change — p=< 0.001
Phase 2 N=3 Exploring Nitrous Oxide Effects for Post Traumatic Stress Disorder (PTSD)
Post Traumatic Stress Disorder
Primary: Number of Patients Who Met and Exceeded Response Criteria of Clinician Administered PTSD Scale for DSM-5 (CAPS-5) — 2 Participants
Phase 2 N=18 Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Metastatic Pancreatic Adenocarcinoma
Primary: Number of Patients Who Experienced a Dose-Limiting Toxicity (DLT) — 9; 8 participants
Phase 2 N=13 HBPL Study of the Impact of the NK1 Antagonist Aprepitant
Cocaine Dependence · Alcohol Dependence
Primary: Cocaine Craving as Measured on the Visual Analog Scale (VAS) 1 — 19; 48 units on a scale — p=0.08
Phase 2 N=271 Safety and Efficacy of Elagolix in Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids
Heavy Uterine Bleeding · Uterine Fibroids
Primary: Mean Change From Baseline to the Last 28 Days of Treatment in Menstrual Blood Loss (MBL) — 213.70; 269.36; 321.73; 335.11 mL — p=< 0.001
Phase 2 N=165 A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Acute Gouty Arthritis
Acute Gouty Arthritis
Primary: Change in Patient-assessed Pain Intensity in the Index Joint From Baseline to 24-72 Hours for the First Gout Flare Treated in the Study as Measured by VAS — -26.1…
Phase 2 N=36 Effect of TAK-954 on Gastrointestinal and Colonic Transit in Diabetic or Idiopathic Gastroparesis Participants
Diabetic Gastroparesis · Idiopathic Gastroparesis
Primary: Percent Change From Baseline in Half-emptying Time (T1/2) of Gastric Solids — 3.5; -19.8; -25.4; -25.7 percent change — p=0.0012
Phase 2 N=96 Study to Evaluate the Safety and Efficacy of 13 Weeks of the Selective Androgen Receptor Modulator (SARM) GSK2881078 in Chronic Obstructive Pulmonary Disease (COPD)
Cachexia
Primary: Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) — 3.0; 2.1; -2.1; 3.1 Millimeters of mercury